The American Medical Association released findings in 2024 documenting accelerating consolidation in the pharmacy benefit management industry, with just four companies now controlling three-quarters of the national market. OptumRx, Express Scripts, CVS Caremark, and Prime Therapeutics collectively manage 75% of all PBM services across the United States.
This concentration level represents a dramatic tightening of control in an industry that intermediates drug pricing and access for millions of Americans. PBMs act as gatekeepers between insurers, employers, pharmacies, and patients. They negotiate drug prices with manufacturers, establish formularies that determine which medications patients can access, and set reimbursement rates that pharmacies receive. When four entities command three-quarters of this market, their decisions affect prescription coverage for the vast majority of covered lives in America.
The AMA's market concentration data carries particular weight because organized medicine has emerged as a vocal critic of PBM practices. Physicians argue that PBM policies routinely obstruct patient access to clinically appropriate medications. Prior authorization requirements delay treatment. Formulary restrictions force patients onto cheaper alternatives regardless of medical necessity. Pharmacy reimbursement cuts strain independent drugstore operations and create pharmacy deserts in underserved areas.
OptumRx operates within UnitedHealth Group, one of the nation's largest health insurers, creating vertical integration that allows the company to coordinate drug benefits with medical benefits in ways competitors cannot match. Express Scripts, owned by Cigna, similarly functions within an integrated insurance framework. CVS Caremark combines retail pharmacy operations with PBM functions and insurance coverage through CVS Health and Aetna. Prime Therapeutics remains the largest independently owned PBM but operates as a cooperative owned by regional health plans.
The concentration reflects a decade of consolidation. Previous mergers included Express Scripts acquiring Medco in 2012, creating the largest PBM at the time. CVS's acquisition of Caremark in 2007 followed by Aetna's merger into CVS Health in 2018 created another powerhouse. UnitedHealth's expansion of OptumRx through acquisitions and organic growth positioned it as a market leader. Each transaction reduced competition and expanded the remaining players' leverage over drug manufacturers, pharmacies, and patients.
Congressional scrutiny has intensified as a result. The Senate Health Committee and House Oversight Committee have held hearings examining PBM practices, with particular focus on spread pricing, where PBMs keep the difference between what they pay pharmacies and what they charge insurers. Some states have enacted PBM licensing requirements and restrictions on certain practices, though federal regulation remains limited.
The concentration data underscores why proposed legislative solutions like PBM transparency requirements and anti-rebate reforms command bipartisan support. When market power concentrates this heavily, structural reform becomes necessary to protect competitive dynamics and patient access.